JP2024535124A5 - - Google Patents
Info
- Publication number
- JP2024535124A5 JP2024535124A5 JP2024538780A JP2024538780A JP2024535124A5 JP 2024535124 A5 JP2024535124 A5 JP 2024535124A5 JP 2024538780 A JP2024538780 A JP 2024538780A JP 2024538780 A JP2024538780 A JP 2024538780A JP 2024535124 A5 JP2024535124 A5 JP 2024535124A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/074596 | 2021-09-07 | ||
| EP2021074596 | 2021-09-07 | ||
| PCT/EP2022/074735 WO2023036774A1 (en) | 2021-09-07 | 2022-09-06 | Antibodies binding to tetanus toxin and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535124A JP2024535124A (ja) | 2024-09-26 |
| JP2024535124A5 true JP2024535124A5 (enExample) | 2025-09-17 |
Family
ID=77864578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538780A Pending JP2024535124A (ja) | 2021-09-07 | 2022-09-06 | 破傷風毒素に結合する抗体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250129142A1 (enExample) |
| EP (1) | EP4399226A1 (enExample) |
| JP (1) | JP2024535124A (enExample) |
| CN (1) | CN118139879A (enExample) |
| WO (1) | WO2023036774A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119161471B (zh) * | 2024-11-19 | 2025-04-01 | 北京科兴中维生物技术有限公司 | 抗破伤风毒素中和抗体及应用 |
| CN120829503B (zh) * | 2025-09-18 | 2025-12-26 | 北京科兴中维生物技术有限公司 | 抗破伤风毒素抗体及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004215125B2 (en) | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
| NZ544924A (en) | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| CN1305904C (zh) * | 2003-12-30 | 2007-03-21 | 龚小迪 | 人源的抗破伤风毒素单克隆抗体的制备和应用 |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| EP3733699A4 (en) * | 2017-12-29 | 2022-06-08 | Zhuhai Trinomab Biotechnology Co., Ltd. | FULLY HUMANIZED MONOCLONAL NEUTRALIZING ANTIBODY FOR TETANUS TOXIN AND ITS USE |
-
2022
- 2022-09-06 CN CN202280060150.4A patent/CN118139879A/zh active Pending
- 2022-09-06 US US18/689,768 patent/US20250129142A1/en active Pending
- 2022-09-06 EP EP22776904.9A patent/EP4399226A1/en not_active Withdrawn
- 2022-09-06 JP JP2024538780A patent/JP2024535124A/ja active Pending
- 2022-09-06 WO PCT/EP2022/074735 patent/WO2023036774A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773157B2 (en) | Compositions and methods for treating and preventing Staphylococcus aureus infections | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| JP2010516229A5 (enExample) | ||
| JP2022512647A5 (enExample) | ||
| US20220324949A1 (en) | Anti-alpha-hemolysin antibody and use thereof | |
| US20240262894A1 (en) | Antibody against respiratory syncytial virus and use thereof | |
| JP2024016024A5 (enExample) | ||
| JP2022512646A5 (enExample) | ||
| JP2024535124A5 (enExample) | ||
| US20250059266A1 (en) | Antibodies for treating alpha-synucleinopathies | |
| JP2023182689A5 (enExample) | ||
| US20250129141A1 (en) | Antibody for tetanus toxin and use thereof | |
| JPWO2022044573A5 (enExample) | ||
| JP2021155416A5 (enExample) | ||
| JP2022531552A5 (enExample) | ||
| US20240059764A1 (en) | ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF | |
| JP2021525512A5 (enExample) | ||
| US20040198960A1 (en) | Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae | |
| US20240010711A1 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| JP2025063187A5 (enExample) | ||
| AU2008332943B9 (en) | G immunoglobulin used against anthrax toxins | |
| JP2023552846A5 (enExample) | ||
| HK40065443A (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| JPWO2023153471A5 (enExample) | ||
| JP2023544614A5 (enExample) |